On October 31, 2017 Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, reported it will present third quarter 2017 results to investors and analysts in a conference call on October 31, 2017 at 8:30am EDT, hosted by Nessan Bermingham, Ph.D., Chief Executive Officer and Founder, John Leonard, M.D., Executive Vice President, R&D, and Graeme Bell, Chief Financial Officer (Press release, Intellia Therapeutics, OCT 30, 2017, View Source [SID1234521356]). The analyst and investor presentation can be downloaded starting at 8:00am EDT from the Investor Relations section of the company’s website at www.intelliatx.com. A replay of the call will be available on Intellia’s website, beginning on October 31 at 11:00am EDT, 2017.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate on the day of the call:

U.S. callers should dial 888-752-0423 and use Conference ID# 9089048, approximately five minutes before the call.
International callers should dial +1 918-398-4936 and use Conference ID# 9089048, approximately five minutes before the call.
To listen to the replay:

U.S. callers should dial 855-859-2056, Conference ID# 9089048.
International callers should dial +1 404-537-3406, Conference ID# 9089048.